M
Magnus Dahlbom
Researcher at University of California, Los Angeles
Publications - 204
Citations - 9017
Magnus Dahlbom is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Imaging phantom & Iterative reconstruction. The author has an hindex of 49, co-authored 200 publications receiving 8461 citations. Previous affiliations of Magnus Dahlbom include University of Texas MD Anderson Cancer Center & Oak Ridge National Laboratory.
Papers
More filters
Journal ArticleDOI
The Ecat Exact Hr - Performance of a New High-resolution Positron Scanner
Klaus Wienhard,Magnus Dahlbom,Lars Eriksson,Christian Michel,T. Bruckbauer,Uwe Pietrzyk,Wolf-Dieter Heiss +6 more
TL;DR: Due to its special properties, the ECAT EXACT HR can be equally applied to routine clinical brain and whole-body imaging and to noninvasive experimental studies of regional tracer concentrations in medium-sized animals.
Journal Article
Evaluation of the Skeletal Kinetics of Fluorine-18-Fluoride Ion with PET
Randall A. Hawkins,Yong Choi,Sung-Cheng Huang,Carl K. Hoh,Magnus Dahlbom,Christiaan Schiepers,Nagichettiar Satyamurthy,Jorge R. Barrio,Michael E. Phelps +8 more
TL;DR: The skeletal kinetics of [18F]fluoride ion with dynamic PET imaging is investigated to generate quantitative estimates of fluoride uptake (a "bone metabolic index") in focal skeletal regions or in more generalized distributions.
Journal ArticleDOI
Striatal Dopamine D2/D3 Receptor Availability Is Reduced in Methamphetamine Dependence and Is Linked to Impulsivity
Buyean Lee,Edythe D. London,Russell A. Poldrack,Judah Farahi,Angelo Nacca,John Monterosso,Jeanette A. Mumford,Andrew V. Bokarius,Magnus Dahlbom,Jogeshwar Mukherjee,Robert M. Bilder,Arthur L. Brody,M. Mandelkern +12 more
TL;DR: The findings suggest that low striatal D2/D3 receptor availability may mediate impulsive temperament and thereby influence addiction.
Journal ArticleDOI
18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.
Jeremie Calais,Francesco Ceci,Francesco Ceci,Matthias Eiber,Matthias Eiber,Thomas A. Hope,Michael S Hofman,Christoph Rischpler,Tore Bach-Gansmo,Cristina Nanni,Bital Savir-Baruch,David Elashoff,Tristan Grogan,Magnus Dahlbom,Roger Slavik,Jeannine Gartmann,Kathleen Nguyen,Vincent Lok,Hossein Jadvar,Amar U. Kishan,Matthew Rettig,Robert E. Reiter,Wolfgang P. Fendler,Wolfgang P. Fendler,Johannes Czernin +24 more
TL;DR: Comparing prospectively paired 18F-fluciclovine and PSMA PET-CT scans for localising biochemical recurrence of prostate cancer after radical prostatectomy in patients with low prostate-specific antigen (PSA) concentrations found PSMA should be the PET tracer of choice when PET- CT imaging is considered for subsequent treatment management decisions.
Journal ArticleDOI
Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma
Gregory A. Wiseman,Christine A. White,Michael Stabin,William L. Dunn,William D. Erwin,Magnus Dahlbom,Andrew Raubitschek,Kastytis Karvelis,Timothy E. Schultheiss,Thomas E. Witzig,Richard Belanger,Stewart Spies,Daniel H.S. Silverman,Judy R. Berlfein,Eric Ding,Antonio J. Grillo-Lopez +15 more
TL;DR: It is concluded that 90Y-Zevalin administered at nonmyeloablative maximum tolerated doses results in acceptable radiation absorbed doses to normal organs and bone marrow from non-Hodgkin’s lymphoma treatment.